Quantitative systems pharmacology: Landscape analysis of regulatory submissions to the US Food and Drug Administration

被引:36
|
作者
Bai, Jane P. F. [1 ]
Earp, Justin C. [1 ]
Florian, Jeffry [1 ]
Madabushi, Rajanikanth [1 ]
Strauss, David G. [1 ]
Wang, Yaning [1 ]
Zhu, Hao [1 ]
机构
[1] US FDA, Off Clin Pharmacol, Ctr Drug Evaluat & Res, Silver Spring, MD USA
来源
关键词
D O I
10.1002/psp4.12709
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Quantitative systems pharmacology (QSP) has been proposed as a scientific domain that can enable efficient and informative drug development. During the past several years, there has been a notable increase in the number of regulatory submissions that contain QSP, including Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Biologics License Applications (BLAs) to the US Food and Drug Administration. However, there has been no comprehensive characterization of the nature of these regulatory submissions regarding model details and intended applications. To address this gap, a landscape analysis of all the QSP submissions as of December 2020 was conducted. This report summarizes the (1) yearly trend of submissions, (2) proportion of submissions between INDs and NDAs/BLAs, (3) percentage distribution along the stages of drug development, (4) percentage distribution across various therapeutic areas, and (5) nature of QSP applications. In brief, QSP is increasingly applied to model and simulate both drug effectiveness and safety throughout the drug development process across disease areas.
引用
收藏
页码:1479 / 1484
页数:6
相关论文
共 50 条
  • [41] Quantitative Systems Pharmacology: A Regulatory Perspective on Translation
    Zineh, Issam
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2019, 8 (06): : 336 - 339
  • [42] Translational Quantitative Systems Pharmacology in Drug Development: from Current Landscape to Good Practices
    Bai, Jane P. F.
    Earp, Justin C.
    Pillai, Venkateswaran C.
    AAPS JOURNAL, 2019, 21 (04):
  • [43] Translational Quantitative Systems Pharmacology in Drug Development: from Current Landscape to Good Practices
    Jane P. F. Bai
    Justin C. Earp
    Venkateswaran C. Pillai
    The AAPS Journal, 21
  • [44] US Food and Drug Administration analysis of strokes associated with raloxifene
    Wyeth, Jo
    Green, Lanh
    Avigan, Mark
    OBSTETRICS AND GYNECOLOGY, 2007, 109 (04): : 999 - 999
  • [45] Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980-2022
    Seoane-Vazquez, Enrique
    Rodriguez-Monguio, Rosa
    Powers III, John H.
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [46] US Food and Drug Administration Updates
    Sahin, L.
    BIRTH DEFECTS RESEARCH, 2018, 110 (09): : 748 - 748
  • [47] Urokinase and the US food and drug administration
    Ouriel, K
    JOURNAL OF VASCULAR SURGERY, 1999, 30 (05) : 957 - 958
  • [48] Independence at the US Food and Drug Administration
    不详
    LANCET, 2006, 367 (9523): : 1630 - 1630
  • [49] Transparency at the US Food and Drug Administration
    Califf, Robert M.
    JOURNAL OF LAW MEDICINE & ETHICS, 2017, 45 : 24 - 28
  • [50] Regulatory Research to Support Food-Contact Infant Safety Assessment at US Food and Drug Administration
    Neal-Kluever, A. P.
    Aungst, J.
    Wu, Y.
    Liu, J.
    Shackelford, M.
    Ogungbesan, A.
    Gu, Y.
    Jacobs, K.
    BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, 2016, 106 (05) : 404 - 404